Advances in targeted therapy for non-small cell lung cancer

You will learn:
• To understand that recent developments in tumour biology and oncogenes, technologies including diagnostic scanning, therapeutic radiotherapy, and targeted therapies, have significantly improved diagnosis, prognosis and quality of life for patients with non-small cell lung cancer (NSCLC) 
• That as a group, mutations that are amenable to treatment with targeted therapy account for approximately 50% of all NSCLCs
• An understanding of targeted therapies, including the small molecule inhibitors (e.g. tyrosine kinase inhibitors) that inhibit up regulated pathways involved in regulation of cell growth, proliferation and survival.